Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on May 21, 2025
Rapport Therapeutics to Host 2025 Investor and Analyst Day
GlobeNewswire
·
May 21, 2025
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or …
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
GlobeNewswire
·
May 21, 2025
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carolina (UNC) and supported by a grant …
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 21, 2025
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company …
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewswire
·
May 21, 2025
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in …
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
GlobeNewswire
·
May 21, 2025
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo …
NeurAxis Announces $5.0 Million Registered Direct Offering
GlobeNewswire
·
May 21, 2025
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 21, 2025
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
Verano to Celebrate Grand Opening of Zen Leaf Enfield, Company’s Seventh Connecticut Dispensary, Throughout Memorial Day Weekend
GlobeNewswire
·
May 21, 2025
Zen Leaf Enfield, located at 98 Elm St., adjacent to Enfield Square Mall, joins the local business community ahead of the Mall’s $250 million transformative redevelopment to “Enfield Marketplace” Verano provided funds to the Thompsonville Fire Department …
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
GlobeNewswire
·
May 21, 2025
PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which transforms into technetium-99, is a critical isotope used in …
EuroPCR 2025: Aktuelle Daten belegen: Die Ereignisraten nach drei Jahren sind beim DynamX® Bioadaptor von Elixir Medical anhaltend signifikant niedriger als bei medikamentenfreisetzenden Stents
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – – Signifikant niedrigere Herztodrate (0,5 % vs. 3,2 %, p = 0, …
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with …
EuroPCR 2025: Los datos más recientes demuestran que el bioadaptador DynamX® de Elixir Medical ofrece tasas significativamente menores de acontecimientos adversos a lo largo de tres años en comparación con el stent liberador de fármaco
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con DynamX® en comparación con SLF— —Tasa significativamente menor …
EuroPCR 2025 : Des données récentes démontrent une réduction durable et statistiquement significative des taux d’événements avec le bioadaptateur DynamX® d’Elixir Medical par rapport au stent à élution médicamenteuse (SEM) sur trois ans
GlobeNewswire
·
May 21, 2025
Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX® par rapport au SEM— —Taux de décès cardiaque significativement inférieur (0,5 % contre 3,2 …
EuroPCR 2025: i dati più recenti dimostrano una riduzione duratura e significativa dei tassi di eventi fino a tre anni con il bioadattatore DynamX® di Elixir Medical rispetto allo stent a rilascio di farmaco
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durata sostenuta dell’efficacia del trattamento con tassi di TLF significativamente inferiori (2,7% vs. 7,2%, p=0,030) con DynamX® rispetto al DES— —Tasso significativamente inferiore di morte cardiaca (0,5% vs. 3, …
EuroPCR 2025: Najnowsze dane potwierdzają trwały i istotnie niższy odsetek niepożądanych zdarzeń klinicznych przy zastosowaniu bioadaptatora DynamX® firmy Elixir Medical w porównaniu do stentu uwalniającego lek (DES) w okresie trzech lat
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- — Trwały efekt terapeutyczny z istotnie niższym współczynnikiem niepowodzeń leczenia zmiany docelowej (TLF) – 2,7% wobec 7,2% (p=0,030) dla DynamX® w porównaniu do DES — — Istotnie niższy współczynnik zgonów sercowo- …
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
GlobeNewswire
·
May 21, 2025
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profile Trial completion expected by Q4 2025 (including a three-month follow-up period) Tinlarebant has previously …